Table 1 Baseline characteristics of each group
From: Long-term outcomes of patients with 10 or more colorectal liver metastases
1–3 CLM | 4–9 CLM | ⩾10 CLM | |||||
|---|---|---|---|---|---|---|---|
N =9643 | N =2234 | N =529 | P | ||||
Variables | No. | % | No. | % | No. | % | |
Sex: male | 5932 | 61.5 | 1400 | 62.7 | 315 | 59.5 | 0.36 |
Mean age (±s.d.), years | 63.3 (±11) | 60.1 (±11) | 58.5 (±10) | <0.0001 | |||
Primary tumour | |||||||
Location: rectum | 3092 | 32.8 | 737 | 33.8 | 133 | 25.8 | 0.002 |
Stage T3–T4 | 7358 | 87.8 | 1741 | 89.7 | 396 | 90.0 | 0.03 |
Stage N positive | 5253 | 63.1 | 1328 | 69.6 | 319 | 74.4 | <0.0001 |
CLM characteristics | |||||||
Mean number of CLM (±s.d.) | 1.6 (±0.7) | 5.3 (±1.4) | 13.4 (±4) | <0.0001 | |||
Mean maximum tumour size (±s.d.), mm | 37.6 (±28) | 38.9 (±28) | 44.5 (±35) | <0.0001 | |||
Mean CEA level, ng ml−1 | 119.4 (±80) | 123.4 (±79) | 137.1 (±77) | <0.0001 | |||
Distribution: bilobar | 2141 | 22.4 | 1736 | 78.6 | 497 | 94.3 | <0.0001 |
Initially resectable | 7774 | 88.2 | 1283 | 62.6 | 163 | 32.1 | <0.0001 |
Time of occurrence: synchronous | 4650 | 48.6 | 1571 | 71.1 | 458 | 87.1 | <0.0001 |
Concomittant extrahepatic disease | 916 | 9.7 | 238 | 10.9 | 70 | 13.5 | 0.008 |
Perioperative management | |||||||
Preop. MRI | 3497 | 39.7 | 951 | 45.9 | 213 | 44.6 | 0.04 |
Preop. chemotherapy | 3391 | 37.1 | 1329 | 61.9 | 353 | 68.4 | <0.0001 |
Preop. targeted therapy | 1277 | 38.6 | 629 | 47.9 | 208 | 59.3 | <0.0001 |
Progression while on chemotherapya | 261 | 7.7 | 83 | 6.2 | 13 | 3.7 | 0.002 |
Portal vein embolisation | 561 | 6.1 | 424 | 19.5 | 201 | 39.1 | <0.0001 |
Postop. chemotherapy | 3824 | 54.2 | 963 | 56.4 | 191 | 51.3 | 0.12 |
Postop. targeted therapy | 752 | 20.3 | 309 | 32.7 | 83 | 43.9 | <0.0001 |
Early outcomes | |||||||
R0/R1 liver resection | 8742 | 95.0 | 1790 | 85.3 | 346 | 72.8 | <0.0001 |
90-day mortality | 200 | 2.1 | 76 | 3.4 | 25 | 4.8 | 0.0001 |
Grade III–IV morbidityb | 1389 | 16.8 | 363 | 19.0 | 81 | 18.7 | 0.05 |
